Autism Medication Below is a list of drugs and autism medication commonly used to treat certain symptoms in children with Autism Spectrum Disorder, as provided by the National Institutes of Health. Use the search feature above to quickly find the autism medication you're looking for. This site complies with the HONcode standard for trustworthy health information: verify here. *The U.S. Food and Drug Administration has approved Risperdal as autism medication to treat irritability in autistic children and adolescents. This is the first time the FDA approved a drug to treat behavior-related problems associated with autism in children. The drug can be used to treat aggression, deliberate self-injury and temper tantrums. Risperdal is considered an atypical antipsychotic drug manufactured by Janssen Pharmaceutica N.V. in Beerse, Belgium. Recent research found another atypical antipsychotic drug called Abilify or Aripiprazole to be effective for reducing aggression, agitation and self-injury in a small group of children with Autism Spectrum Disorders (Stigler et al., 2004). Didn't find the autism medication you were looking for? Use this search feature to find it. References: Children's Autism Medication Chart 1. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry, 2000; 62 (suppl 4): 10-14. 2. Bowden … Continue reading →

Below is an alphabetical list of trade name drugs or autism medication which are commonly used to treat certain symptoms in persons with Autism Spectrum Disorder, as provided by the National Institutes of Health. This site complies with the HONcode standard for trustworthy health information: verify here. References 1. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry, 2000; 62 (suppl 4): 10-14. 2. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. For the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry, 2000; 57(5): 481-489. 3. Vainionp LK, Rtty J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Annals of Neurology, 1999; 45(4): 444-450. 4. Soames JC. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries. Bipolar Disorder, 2000; 2(1): 37-41. 5. Thase ME, and Sachs GS. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biological Psychiatry, 2000; 48(6): 558-572. 6. Department of Health and Human Services. 1999. Mental Health: A Report of the Surgeon General. Rockville, MD: Department of Health and Human … Continue reading →

The following treatment guidelines are meant as a reference tool only, and are not intended as treatment advice or to replace the clinical decision-making process of psychiatrists or other health professionals who administer these treatments. In clinical practice there are often good reasons why treatment approaches differ from what is described here. The first step is to try to reduce the dose of the antipsychotic medication that may be causing the Parkinsonian symptoms. If this does not work, one option is to switch the medication to a different antipsychotic that has less potent dopamine-blocking actions. Quetiapine and Clozapine are the antipsychotics with the least dopamine-blockade, followed by Olanzapine. The second option is to add an anticholinergic medication. The anticholinergic medication will need to be used on a daily basis in order to control the Parkinsonian symptoms. It should be used at the lowest possible effective dose, and once the Parkinsonian symptoms subside it can be tapered and discontinued, as sometimes the Parkinsonian symptoms will improve with time. The first step is to try to reduce the dose of the antipsychotic medication that may be causing the akathisia. If this does not work, one option is to switch the medication to … Continue reading →

National Institute of Mental Health A Participant's Guide to Mental Health Clinical Research Click here to read ADHD | | Addictions | Anorexia | Anxiety Disorders |Autism|Bulimia | Eating Disorders | Fragile X Syndrome |HEALTHY VOLUNTEERS |Huntington'sDisease| Memory Disorders | Mood Disorders | Obesity | Obsessive-Compulsive Disorder|Pain| Parkinson's Disease|Psychosis | Schizophrenia |SleepDisorders|SubstanceAbuse - Addictions| Tourette's Syndrome HOW TO POST RECRUITMENT NOTICES ON THIS PAGE Adult ADD/ADHD Men and women who have been diagnosed with ADD or ADHD are needed for a 2-day outpatient study at the Johns Hopkins School of Medicine in Baltimore, Maryland. Volunteers with ADHD who have used medications for the treatment of ADHD and those who have never used medications for the treatment of ADHD are needed. Volunteers should be between the ages of 18 and 40 and in general good health. Testing will take place at the Johns Hopkins Hospital and Bayview Medical Center. Study participants will receive compensation, and travel expenses will be covered. Earn up to $300 plus travel expenses. For more information, call 410-550-2588 or 410-550-5295 or email johnshopkins.lab@gmail.com. Collect calls are accepted. Principal Investigator: Una D. McCann, MD (IRB Number: NA_0073552) Children With and Without ADHD - Ages 45 Dr. Mark Mahone … Continue reading →

What are treatments for schizophrenia and the side effects of those treatments? Medications While there are a number of helpful treatments available, medication remains the cornerstone of treatment for people with schizophrenia. These medications are often referred to as antipsychotics since they help decrease the intensity of psychotic symptoms. Many health-care professionals prescribe one of these medications, sometimes in combination of one or more other psychiatric medications, in order to maximize the benefit for the person with schizophrenia. Medications that are thought to be particularly effective in treating positive symptoms of schizophrenia include olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel), ziprasidone (Geodon), aripiprazole (Abilify), paliperidone (Invega), asenapine (Saphis), lurasidone (Latuda), and lloperidone (Fanapt). These medications are the newer group of antipsychotic medications, also called second-generation antipsychotics. They are known for having the ability to work quickly compared to many other psychiatric medications. As a group of medications, side effects that occur most often include sleepiness, dizziness, and increased appetite. Weight gain, which may be associated with higher blood sugar levels, elevated blood lipid levels, and sometimes increased levels of a hormone called prolactin, may also occur. Although older antipsychotic medications in this class like haloperidol (Haldol), perphenazine (Trilafon), and molindone (Moban) … Continue reading →

By Steven Reinberg HealthDay Reporter FRIDAY, Nov. 21, 2014 (HealthDay News) -- Stroke outcomes are better when patients are treated in an ambulance by a neurologist equipped with a CT scanner and clot-busting drugs, German researchers report. The sooner patients get the clot dissolver -- tissue plasminogen activator (tPA) -- the better the outcome after a stroke, the researchers noted. For the best outcome, the drug needs to be given within the first hour after stroke symptoms start, the researchers said. "The so-called 'golden hour' is associated with improved patient outcomes in terms of hospital discharge," said lead researcher Dr. Martin Ebinger, from the Center for Stroke Research at Charite-Universitatsmedizin in Berlin. "Our findings emphasize the importance of fast treatment in acute stroke," he said. Giving clot-busting drugs in a stroke emergency mobile unit (STEMO) substantially increases the number of stroke patients who get that care in the golden hour, Ebinger said. For the study, Ebinger and his colleagues looked at how fast clot-busting drugs could be given before patients got to the hospital and how well they did afterwards. Specifically, they looked at slightly more than 3,000 patients with a suspected stroke treated in a STEMO between May 2011 … Continue reading →

by Jay Crandall azfamily.com Posted on November 24, 2014 at 6:41 PM Updated yesterday at 7:21 PM PHOENIX-- Every year, a stroke will send 800,000 Americans to the hospital. And with every minute that passes, more brain function is lost. There are only about 1,500 stroke experts in the entire country, meaning it would be impossible to put one in every emergency department unless they could literally be in two places at once. What is this? Dr. Victor Zach, Director of Stroke and Neurocritical care at John C. Lincoln, asks a mock patient as he shows us, how he would examine a patient for signs of stroke. But, it turns out, Dr. Zach is not actually bedside for this exam. He is virtually there, thanks to a high-tech robot, This is a cutting edge, In Touch Help, tele-robot that we basically can use to immediately bring a stroke doctor into the room within minutes of a stroke alert activation, he says as he shows us the machine which features a monitor, microphone and cameras. The robot fills a critical need in stroke diagnoses, because there is a shortage of stroke doctors in this country, Dr. Zach explains. To have a … Continue reading →